{"id":400599,"date":"2020-12-16T01:33:23","date_gmt":"2020-12-16T06:33:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400599"},"modified":"2020-12-16T01:33:23","modified_gmt":"2020-12-16T06:33:23","slug":"ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/","title":{"rendered":"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <strong>Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3<\/strong><br \/>\n          \n        <\/li>\n<li>\n          <strong>Joins AB2 Bio from Novartis and has extensive commercial and strategic experience<\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">LAUSANNE, Switzerland, Dec.  16, 2020  (GLOBE NEWSWIRE) &#8212; AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of\u00a0severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief Commercial Officer (CCO).<\/p>\n<p align=\"justify\">Dr Filipovic has more than 20 years of experience as a pharmaceutical executive, covering functions in marketing, strategy, general management at local, regional and global levels as well as in research and development. In his role as CCO of AB2 Bio, Dr Filipovic will be a key member of the Executive Team, responsible for the commercialization of Tadekinig alfa to drive the overall development and growth of the company.<\/p>\n<p align=\"justify\">\u201cWe are very pleased to welcome Djordje Filipovic to AB2 Bio, further strengthening our team as we look forward to results from our Phase 3 study of Tadekinig alfa in Primary Hemophagocytic Lymphohistocytosis, expected mid-2021,\u201d said Michael Soldan, PhD, Chief Executive Officer of AB2 Bio. \u201cDjordje`s leadership and broad experience in launching and commercializing new medicines will be invaluable as we are building the commercial strategy and required capabilities to become a fully integrated biopharma company.\u201d<\/p>\n<p align=\"justify\">Dr Filipovic said: &#8220;I am very excited to join the AB2 Bio team at this important time in the development of the Company and to lead commercialization of Tadekinig alfa as we approach the Phase 3 readout. Tadekinig alfa has the potential to address important unmet needs both in rare, life-threatening auto-inflammatory diseases and in broader cytokine release syndromes, and thus has a significant and growing market opportunity.&#8221;<\/p>\n<p align=\"justify\">Prior to joining AB2 Bio, Dr Filipovic held a number of senior roles at Novartis during his time at the company from 1992, including overseeing the development and commercialization of several key small molecules and monoclonal antibodies. He was also Chairman of the Novartis Oncology Portfolio Management Board. Dr Filipovic obtained his PhD in Biochemistry and Biophysics from the Swiss Federal Institute of Technology (ETH) in Z\u00fcrich.<\/p>\n<p align=\"justify\">\n        <strong>About Tadekinig alfa<br \/><\/strong>Tadekinig alfa is a novel, recombinant human interleukin-18 binding protein (IL-18 BP) inhibiting IL-18, a major proinflammatory cytokine. The Company is developing a pipeline-in-a-product opportunity with Tadekinig alfa in a wide range of IL-18 mediated diseases where hyperinflammation or \u2018cytokine storm\u2019, is an issue, including COVID-19. Tadekinig alfa is currently in late-stage development for the treatment of severe orphan autoinflammatory diseases, including primary and secondary HLH and Still\u2019s disease. Tadekinig alfa has obtained EMA\u2019s Orphan Drug Designation and U.S. FDA\u2019s Orphan Drug Designation, Breakthrough Therapy and Pediatric Rare Disease Designations, making it eligible for a Priority Review Voucher<\/p>\n<p align=\"justify\">\n        <strong>About AB2 Bio Ltd<br \/><\/strong>AB2 Bio is a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of\u00a0severe systemic autoinflammatory diseases,\u00a0including\u00a0rare diseases\u00a0with high unmet medical needs. AB2 Bio is building a late-stage clinical pipeline with Tadeking alfa, a novel IL-18 binding protein with established clinical proof-of-concept in three, life-threatening orphan autoinflammatory indications. The Company is also advancing Tadekinig alfa in preclinical development in oncology and COVID-19 cytokine release syndrome. AB2 Bio is located in the Innovation Park at the Ecole Polytechnique Fe\u0301de\u0301rale de Lausanne (EPFL), Switzerland. More information can be found on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cFs4sbcTbMkH6T-6MrEtawUmdJLkTT0GPl_icY4bT6rJ95oPP9XTOmlJktSfSB9f7_SDjFY0BBoYoRjrwWIh7g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.ab2bio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<br \/><\/strong><br \/>\n        <strong>AB2 Bio<br \/><\/strong>Fernando Cunha<br \/>CFO, AB2 Bio<br \/>Phone +41 21 694 00 48<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XlF6G1OWlWrqffzD22PMvPM89sUCbm7R2hLIaVXkppokZMFhh71ew8MQFmCGl3GJyaENE3mqPHNuGO9rzI-ThQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@ab2bio.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor &amp; Media Relations <\/strong><br \/>\n        <br \/>LifeSci Advisors \u2013 Marieke Vermeersch<br \/>Phone +32 479 490 603<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5eGk5qBa1UlEtLPmCaxv3HG9szp2Ls_ZJ4o_n2csPok934RSkMzaOTozJBX4spS9_sJ3On0gmkub2J-L392T9u8ZvZWNcay_3_WsHePVP-OJT_QtQZVnXYxmjFhrV6hE\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mvermeersch@lifesciadvisors.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3f8fbc8b-6493-4d68-827f-76030b78590f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3 Joins AB2 Bio from Novartis and has extensive commercial and strategic experience LAUSANNE, Switzerland, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of\u00a0severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief Commercial Officer (CCO). Dr Filipovic has more than 20 years of experience as a pharmaceutical executive, covering functions in marketing, strategy, general management at local, regional and global levels as well as in research and development. In his role as CCO of AB2 Bio, Dr Filipovic will be a key member of the Executive Team, responsible for the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400599","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3 Joins AB2 Bio from Novartis and has extensive commercial and strategic experience LAUSANNE, Switzerland, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of\u00a0severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief Commercial Officer (CCO). Dr Filipovic has more than 20 years of experience as a pharmaceutical executive, covering functions in marketing, strategy, general management at local, regional and global levels as well as in research and development. In his role as CCO of AB2 Bio, Dr Filipovic will be a key member of the Executive Team, responsible for the &hellip; Continue reading &quot;AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T06:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer\",\"datePublished\":\"2020-12-16T06:33:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/\"},\"wordCount\":584,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/\",\"name\":\"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==\",\"datePublished\":\"2020-12-16T06:33:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/","og_locale":"en_US","og_type":"article","og_title":"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer - Market Newsdesk","og_description":"Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3 Joins AB2 Bio from Novartis and has extensive commercial and strategic experience LAUSANNE, Switzerland, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of\u00a0severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief Commercial Officer (CCO). Dr Filipovic has more than 20 years of experience as a pharmaceutical executive, covering functions in marketing, strategy, general management at local, regional and global levels as well as in research and development. In his role as CCO of AB2 Bio, Dr Filipovic will be a key member of the Executive Team, responsible for the &hellip; Continue reading \"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T06:33:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer","datePublished":"2020-12-16T06:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/"},"wordCount":584,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/","name":"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==","datePublished":"2020-12-16T06:33:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTkzNCMzODgwNjg3IzUwMDA3MDg0OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab2-bio-appoints-dr-djordje-filipovic-as-chief-commercial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400599"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400599\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}